Astrotech Reports Fiscal Year 2025 Financial Results
Astrotech (NASDAQ:ASTC) reported its fiscal year 2025 results, showing a decrease in revenue to $1.0 million due to lower device sales at its 1st Detect subsidiary. The company maintained a slight improvement in gross margin at 45.3% compared to 45.1% in the previous year.
Key developments include the formation of EN-SCAN, a new subsidiary for environmental testing, the launch of an enhanced TRACER 1000 Narcotics Trace Detector, and securing a DHS research contract. The TRACER 1000 is now deployed in 34 locations across 16 countries. The company maintains a strong financial position with $18.2 million in cash and investments as of June 30, 2025.
Astrotech (NASDAQ:ASTC) ha riportato i risultati dell'anno fiscale 2025, con un calo dei ricavi a 1,0 milioni di dollari a causa delle minori vendite di dispositivi della controllata 1st Detect. La marginalità lorda è rimasta leggermente migliore al 45,3% rispetto al 45,1% dell'anno precedente. Tra gli sviluppi chiave figurano la creazione di EN-SCAN, una nuova controllata per i test ambientali, il lancio del TRACER 1000 Narcotics Trace Detector potenziato e l'ottenimento di un contratto di ricerca con il DHS. Il TRACER 1000 è ora impiegato in 34 sedi in 16 paesi. L'azienda mantiene una solida posizione finanziaria con 18,2 milioni di dollari in cassa e investimenti al 30 giugno 2025.
Astrotech (NASDAQ:ASTC) informó sus resultados del año fiscal 2025, con una caída de los ingresos a 1,0 millones de dólares debido a menores ventas de dispositivos en su filial 1st Detect. El margen bruto se mantuvo en una ligera mejora de 45,3% frente al 45,1% del año anterior. Entre los desarrollos clave se destacan la formación de EN-SCAN, una nueva subsidiaria para pruebas ambientales, el lanzamiento del TRACER 1000 Narcotics Trace Detector mejorado y la obtención de un contrato de investigación con DHS. El TRACER 1000 ya está desplegado en 34 ubicaciones en 16 países. La compañía mantiene una posición financiera sólida con 18,2 millones de dólares en efectivo e inversiones al 30 de junio de 2025.
Astrotech (NASDAQ:ASTC)가 2025 회계연도 실적을 발표했으며, 자회사 1st Detect의 기기 매출 감소로 매출이 100만 달러로 감소했습니다. 총이익률은 지난해의 45.1%에서 45.3%EN-SCAN의 설립, 환경 테스트를 위한 신규 자회사, 향상된 TRACER 1000 Narcotics Trace Detector의 출시, DHS 연구 계약 확보가 있습니다. TRACER 1000은 현재 16개국의 34개 장소에서 배치되어 있습니다. 2025년 6월 30일 기준 현금 및 투자금은 1820만 달러로 강한 재무 상태를 유지하고 있습니다.
Astrotech (NASDAQ:ASTC) a publié ses résultats pour l’exercice 2025, avec une baisse du chiffre d’affaires à 1,0 million de dollars en raison de ventes d’appareils plus faibles chez la filiale 1st Detect. La marge brute est restée légèrement meilleure à 45,3% contre 45,1% l’exercice précédent. Parmi les développements clés figurent la création de EN-SCAN, une nouvelle filiale pour les tests environnementaux, le lancement du TRACER 1000 Narcotics Trace Detector amélioré et l’obtention d’un contrat de recherche avec le DHS. Le TRACER 1000 est désormais déployé dans 34 sites à travers 16 pays. L’entreprise conserve une solide position financière avec 18,2 millions de dollars en liquidités et investissements au 30 juin 2025.
Astrotech (NASDAQ:ASTC) meldete die Ergebnisse für das Geschäftsjahr 2025, wobei der Umsatz aufgrund geringerer Gerätevetriebe der Tochter 1st Detect auf 1,0 Mio. USD zurückging. Die Bruttomarge blieb leicht besser bei 45,3% gegenüber 45,1% im Vorjahr. Zu den wichtigsten Entwicklungen gehören die Gründung von EN-SCAN, einer neuen Tochtergesellschaft für Umweltprüfungen, die Einführung des verbesserten TRACER 1000 Narcotics Trace Detector und der Abschluss eines DHS-Forschungsauftrags. Der TRACER 1000 ist nun an 34 Standorten in 16 Ländern im Einsatz. Das Unternehmen verfügt am 30. Juni 2025 über eine starke finanzielle Position mit 18,2 Mio. USD in Bar und Investments.
Astrotech (NASDAQ:ASTC) أعلنت عن نتائجها للسنة المالية 2025، مع انخفاض الإيرادات إلى 1000000 دولار بسبب انخفاض مبيعات الأجهزة لدى الشركة التابعة 1st Detect. حافظت الشركة على هامش إجمالي تقريبي محسّن قليلاً إلى 45.3% مقارنة بـ 45.1% في العام السابق. من التطورات الرئيسية تشكيل EN-SCAN، وهي شركة فرعية جديدة للاختبارات البيئية، وإطلاق TRACER 1000 Narcotics Trace Detector المحسّن، والحصول على عقد بحث مع DHS. تُوزَّع TRACER 1000 حالياً في 34 موقعاً عبر 16 دولة. وتتمتع الشركة بوضع مالي قوي مع 18.2 مليون دولار نقداً واستثمارات حتى 30 يونيو 2025.
Astrotech (NASDAQ:ASTC) 公布了2025财年业绩,由于其子公司 1st Detect 的设备销量下降,收入降至 100万美元。毛利率保持小幅提升至 45.3%,高于上一年的 45.1%。主要进展包括成立用于环境测试的新子公司 EN-SCAN、推出增强版 TRACER 1000 Narcotics Trace Detector,以及获得 DHS 的研究合同。TRACER 1000 现已在 16个国家的34个地点 投入使用。公司截至 2025年6月30日 的现金及投资总额为 1820万美元,财务状况强劲。
- None.
- Revenue declined due to lower device sales at 1st Detect subsidiary
Insights
Astrotech reports mixed results with revenue decline but strong cash position and strategic expansion into new markets.
Astrotech's fiscal year 2025 results reveal contrasting financial signals. Revenue decreased to
The company's strategic expansion is notable on multiple fronts. The formation of EN-SCAN represents a calculated diversification into environmental testing applications, leveraging their proprietary mass spectrometer technology. This move addresses growing market demand for real-time environmental monitoring solutions. Meanwhile, 1st Detect has expanded its international footprint with its TRACER 1000 now deployed across 34 locations in 16 countries spanning three continents.
The R&D contract (70RSAT24CB0000015) with the Department of Homeland Security for next-generation explosives trace detection development is particularly significant. Government contracts typically provide stable revenue streams and validation of technology, potentially opening doors to larger deployments. Additionally, the Vietnam deployment marks meaningful progress in Southeast Asian market penetration.
Despite current revenue challenges, Astrotech's technology diversification, international expansion, and strong liquidity position the company for potential growth, though execution of their commercialization strategy remains critical for reversing the revenue decline trend.
AUSTIN, Texas, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Astrotech Corporation (Nasdaq: ASTC) (the “Company” or “Astrotech”) reported its financial results for the fiscal year ended June 30, 2025.
Financial Highlights & Fiscal Year Developments
- Revenue decreased to
$1.0 million as Astrotech’s subsidiary, 1st Detect, sold less devices compared to prior year. Gross margin increased to45.3% for the year compared to45.1% in the prior year, due to device sales in fiscal year 2025 having a higher margin compared to the device sales in fiscal year 2024. - As of June 30, 2025, the Company has deployed the TRACER 1000 in approximately 34 locations in 16 countries across the United States, Europe and Asia.
- The Company announced the formation of a new wholly owned subsidiary, EN-SCAN, Inc. to manufacture and sell a new line of instruments built for environmental testing applications using its proprietary ATi Gas Chromatograph and Astrotech Mass Spectrometer Technology for outdoor field work for on-site, real-time air, water, and soil analysis providing instant feedback for accurate contamination source location and migration. With a focus on real-time monitoring, EN-SCAN is expected to enable organizations to make data-driven decisions while reducing testing costs and time delays.
- 1st Detect Corporation launched its enhanced TRACER 1000 Narcotics Trace Detector. The TRACER 1000 NTD is a high-performance laboratory instrument capable of rapid detection of trace levels of narcotic compounds in seconds. The TRACER 1000 NTD and the TRACER 1000 ETD together provide a comprehensive protection platform that can be applied across various markets including airports, border security, checkpoint, cargo, infrastructure security, correctional facilities, military, and law enforcement.
- On January 14, 2025, our 1st Detect subsidiary announced that it was awarded research and development contract 70RSAT24CB0000015 with the Department of Homeland Security (“DHS”) to research, develop and mature the TRACER 1000 for DHS next generation explosives trace detection.
- 1st Detect Corporation made its first sale and deployment of its TRACER 1000 Narcotics Trace Detector in Vietnam. This milestone marks a significant step in expanding the 1st Detect footprint across Southeast Asia and reinforces its commitment to enhancing narcotics trace detection inspection capabilities.
- Astrotech’s consolidated balance sheet consisted of
$18.2 million in cash and cash equivalents and liquid investments as of June 30, 2025, which the Company believes will support the Company’s organic growth and research and development.
“Our mission is simple - to make the benefits of precise mass spectrometry and gas chromatography accessible to organizations in our focus markets. Our mass spectrometry products have a strong international presence, serving multiple markets. Our gas chromatography products deliver meaningful advantages by meeting real-time, on-site industry demands. Our servicing has been expanded, and we now serve Asia, Europe and the United States. We believe our sales team’s commitment to excellence and their ability to respond to market opportunities will drive our growth in the next fiscal year,” stated Thomas B. Pickens, III, Astrotech’s Chairman, Chief Executive Officer and Chief Technology Officer.
About Astrotech Corporation
Astrotech (Nasdaq: ASTC) is a mass spectrometry company that creates, operates, and scales innovative businesses through its wholly owned subsidiaries. Each subsidiary leverages Astrotech’s core technology to serve specialized markets:
- 1st Detect develops, manufactures, and markets trace detection systems for security and narcotics screening applications.
- AgLAB designs process analyzers tailored to the agriculture industry.
- Pro-Control produces solutions for in-situ chemical process control in industrial manufacturing.
- BreathTech is advancing a breath analysis platform to detect volatile organic compounds (VOCs) associated with infections and critical health conditions.
- EN-SCAN, Inc. delivers portable, ruggedized environmental testing solutions that integrate gas chromatography and mass spectrometry for use in challenging field environments.
Forward-Looking Statements
This press release contains “forward-looking statements” that are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks, trends, and uncertainties that could cause actual results to be materially different from the forward-looking statement. These statements may be identified by terms such as “aims,” “anticipates,” “believes,” contemplates,” “continue,” “could,” “estimates,” “expect,” “forecast,” “guidance,” “intends,” “may,” “plans,” “possible,” “potential,” “predicts,” “preliminary,” “projects,” “seeks,” “should,” “targets,” “will” or “would,” or the negatives of these terms, variations of these terms or other similar expressions. These factors include, but are not limited to, the adverse impact of inflationary pressures, including significant increases in fuel costs, global economic conditions and events related to these conditions, including the ongoing wars in Ukraine and the middle east, the Company’s use of proceeds from the common stock offerings, whether we can successfully complete the development of our new products and proprietary technologies, whether we can obtain the FDA and other regulatory approvals required to market our products under development in the United States or abroad, whether the market will accept our products and services and whether we are successful in identifying, completing and integrating acquisitions, as well as other risk factors and business considerations described in the Company’s Securities and Exchange Commission filings including the Company’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Any forward-looking statements in this document should be evaluated in light of these important risk factors. While we do not intend to directly harvest, manufacture, distribute or sell cannabis or cannabis products, we may be detrimentally affected by a change in enforcement by federal or state governments and we may be subject to additional risks in connection with the evolving regulatory area and associated uncertainties. Any such effects may give rise to risks and uncertainties that are currently unknown or amplify others mentioned herein. Although the Company believes the expectations reflected in its forward-looking statements are reasonable and are based on reasonable assumptions, no assurance can be given that these assumptions are accurate or that any of these expectations will be achieved (in full or at all) or will prove to have been correct. Moreover, such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of the Company, which may cause actual results to differ materially from those implied or expressed by the forward-looking statements. In addition, any forward- looking statements included in this press release represent the Company’s views only as of the date of its publication and should not be relied upon as representing its views as of any subsequent date. The Company assumes no obligation to correct or update these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
Company Contact:
Jennifer Cañas
Chief Financial Officer, Astrotech Corporation
(512) 485-9530
Investor Contact:
Matt Kreps
Managing Director, Darrow Associates
(214) 597-8200 mkreps@darrowir.com
Tables follow ASTROTECH CORPORATION Consolidated Statements of Operations and Comprehensive Loss (In thousands, except per share data) (Unaudited) | ||||||||
Years Ended | ||||||||
June 30, | ||||||||
2025 | 2024 | |||||||
Revenue | $ | 1,049 | $ | 1,664 | ||||
Cost of revenue | 574 | 913 | ||||||
Gross profit | 475 | 751 | ||||||
Operating expenses: | ||||||||
Selling, general and administrative | 7,067 | 7,241 | ||||||
Research and development | 8,142 | 6,790 | ||||||
Total operating expenses | 15,209 | 14,031 | ||||||
Loss from operations | (14,734 | ) | (13,280 | ) | ||||
Other income and expense, net | 886 | 1,616 | ||||||
Loss from operations before income taxes | (13,848 | ) | (11,664 | ) | ||||
Income tax benefit /(expense) | (2 | ) | (2 | ) | ||||
Net loss | $ | (13,850 | ) | $ | (11,666 | ) | ||
Weighted average common shares outstanding: | ||||||||
Basic and diluted | 1,665 | 1638 | ||||||
Basic and diluted net loss per common share: | ||||||||
Net loss per common share | $ | (8.32 | ) | $ | (7.12 | ) | ||
Other comprehensive loss, net of tax: | ||||||||
Net loss | $ | (13,850 | ) | $ | (11,666 | ) | ||
Available-for-sale securities: | ||||||||
Net unrealized gain | 313 | 276 | ||||||
Total comprehensive loss | $ | (13,537 | ) | $ | (11,390 | ) | ||
ASTROTECH CORPORATION Consolidated Balance Sheets (In thousands, except share and per share data) (Unaudited) | ||||||||
June 30, | ||||||||
2025 | 2024 | |||||||
Assets | ||||||||
Current assets | ||||||||
Cash and cash equivalents | $ | 3,100 | $ | 10,442 | ||||
Short-term investments | 15,108 | 21,474 | ||||||
Accounts receivable | 485 | 77 | ||||||
Inventory, net: | ||||||||
Raw materials | 2,194 | 2,038 | ||||||
Work-in-process | 425 | 66 | ||||||
Finished goods | 310 | 370 | ||||||
Prepaid expenses and other current assets | 353 | 261 | ||||||
Total current assets | 21,975 | 34,728 | ||||||
Property and equipment, net | 2,395 | 2,763 | ||||||
Intangible assets, net | 48 | - | ||||||
Operating lease right-of-use assets, net | 2,225 | 119 | ||||||
Other assets, net | 346 | 30 | ||||||
Total assets | $ | 26,989 | $ | 37,640 | ||||
Liabilities and stockholders’ equity | ||||||||
Current liabilities | ||||||||
Accounts payable | $ | 1,066 | $ | 373 | ||||
Payroll related accruals | 529 | 1,174 | ||||||
Accrued expenses and other liabilities | 451 | 754 | ||||||
Lease liabilities, current | 405 | 227 | ||||||
Total current liabilities | 2,451 | 2,528 | ||||||
Accrued expenses and other liabilities, net of current portion | 164 | 232 | ||||||
Lease liabilities, net of current portion | 2,274 | 73 | ||||||
Total liabilities | 4,889 | 2,833 | ||||||
Commitments and contingencies (Note 13) | ||||||||
Stockholders’ equity | ||||||||
Convertible preferred stock, | - | - | ||||||
Common stock, | 190,643 | 190,643 | ||||||
Treasury shares, 10,316 shares at June 30, 2025 and 2024, respectively | (119 | ) | (119 | ) | ||||
Additional paid-in capital | 83,310 | 82,480 | ||||||
Accumulated deficit | (250,870 | ) | (237,020 | ) | ||||
Accumulated other comprehensive loss | (864 | ) | (1,177 | ) | ||||
Total stockholders’ equity | 22,100 | 34,807 | ||||||
Total liabilities and stockholders’ equity | $ | 26,989 | $ | 37,640 |
